IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 118 filers reported holding IMMUNOVANT INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,611,575 | +312.8% | 328,512 | +104.0% | 0.00% | +300.0% |
| Q2 2023 | $3,055,043 | +102.2% | 161,046 | +65.3% | 0.00% | 0.0% |
| Q1 2023 | $1,511,015 | -73.3% | 97,422 | -69.5% | 0.00% | -66.7% |
| Q4 2022 | $5,663,510 | +6192.8% | 319,071 | +1881.1% | 0.00% | – |
| Q3 2022 | $90,000 | -60.2% | 16,106 | -60.9% | 0.00% | – |
| Q1 2022 | $226,000 | -79.2% | 41,178 | -67.7% | 0.00% | – |
| Q4 2021 | $1,087,000 | -82.3% | 127,554 | -81.9% | 0.00% | -100.0% |
| Q3 2021 | $6,125,000 | -34.8% | 704,856 | -20.7% | 0.00% | -33.3% |
| Q2 2021 | $9,392,000 | +4228.1% | 888,518 | +6459.3% | 0.00% | – |
| Q1 2021 | $217,000 | -58.1% | 13,546 | -7.9% | 0.00% | – |
| Q3 2020 | $518,000 | -19.1% | 14,713 | -44.1% | 0.00% | – |
| Q2 2020 | $640,000 | +244.1% | 26,321 | +119.5% | 0.00% | – |
| Q1 2020 | $186,000 | – | 11,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |